Epstein-Barr virus deubiquitinase downregulates TRAF6-mediated NF-κB signaling during productive replication

Journal of Virology

Volumn 87, Issue 7, 2013, Pages 4060-4070

  Saito, Shinichi ^a   Murata, Takayuki ^a   Kanda, Teru ^a   Isomura, Hiroki ^a   Narita, Yohei ^a,b   Sugimoto, Atsuko ^a,b   Kawashima, Daisuke ^a   Tsurumi, Tatsuya ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS DEUBIQUITINASE; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LATENT MEMBRANE PROTEIN 1; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG; VIRUS ENZYME;

ARTICLE; CATALYSIS; CONTROLLED STUDY; DNA FRAGMENTATION; DNA REPLICATION; DOWN REGULATION; ENZYME PHOSPHORYLATION; ENZYME REACTIVATION; EPSTEIN BARR VIRUS; GENE EXPRESSION; HUMAN; HUMAN CELL; LIFE CYCLE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; REPORTER GENE; SIGNAL TRANSDUCTION; UBIQUITINATION; UPREGULATION; VIRUS GENOME; VIRUS REPLICATION;

ANALYSIS OF VARIANCE; CHROMOSOMES, ARTIFICIAL, BACTERIAL; DNA PRIMERS; HEK293 CELLS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LUCIFERASES; MUTAGENESIS; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 6; TRANSFECTION; UBIQUITINATION; VIRAL MATRIX PROTEINS; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIRUS REPLICATION;

HERPESVIRIDAE; HUMAN HERPESVIRUS 4;

EID: 84875514442     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02020-12     Document Type: Article

References (83)

1. Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, Gibson TJ, Hatfull G, Hudson GS, Satchwell SC, Séguin C, Tuffnell PS, Barrell BG. 1984. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature. 310:207-211.
2. Morrison JA, Gulley ML, Pathmanathan R, Raab-Traub N. 2004. Differential signaling pathways are activated in the Epstein-Barr virusassociated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma. Cancer Res. 64:5251-5260.
3. Wu S, Xie P, Welsh K, Li C, Ni CZ, Zhu X, Reed JC, Satterthwait AC, Bishop GA, Ely KR. 2005. LMP1 protein from the Epstein-Barr virus is a structural CD40 decoy in B lymphocytes for binding to TRAF3. J. Biol. Chem. 280:33620-33626.
4. Xie P, Bishop GA. 2004. Roles of TNF receptor-associated factor 3 in signaling to B lymphocytes by carboxyl-terminal activating regions 1 and 2 of the EBV-encoded oncoprotein latent membrane protein 1. J. Immunol. 173:5546-5555.
5. Schultheiss U, Puschner S, Kremmer E, Mak TW, Engelmann H, Hammerschmidt W, Kieser A. 2001. TRAF6 is a critical mediator of signal transduction by the viral oncogene latent membrane protein 1. EMBO J. 20:5678-5691.
6. Wu L, Nakano H, Wu Z. 2006. The C-terminal activating region 2 of the Epstein-Barr virus-encoded latent membrane protein 1 activates NFkappaB through TRAF6 and TAK1. J. Biol. Chem. 281:2162-2169.
7. Bishop GA, Hostager BS. 2001. Signaling by CD40 and its mimics in B cell activation. Immunol. Res. 24:97-109.
8. Xie P, Hostager BS, Bishop GA. 2004. Requirement for TRAF3 in signaling by LMP1 but not CD40 in B lymphocytes. J. Exp. Med. 199:661-671.
9. Eliopoulos AG, Blake SM, Floettmann JE, Rowe M, Young LS. 1999. Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J. Virol. 73:1023-1035.
10. Eliopoulos AG, Gallagher NJ, Blake SM, Dawson CW, Young LS. 1999. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J. Biol. Chem. 274:16085-16096.
11. Gires O, Kohlhuber F, Kilger E, Baumann M, Kieser A, Kaiser C, Zeidler R, Scheffer B, Ueffing M, Hammerschmidt W. 1999. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J. 18:3064-3073.
12. Higuchi M, Kieff E, Izumi KM. 2002. The Epstein-Barr virus latent membrane protein 1 putative Janus kinase 3 (JAK3) binding domain does not mediate JAK3 association or activation in B-lymphoma or lymphoblastoid cell lines. J. Virol. 76:455-459.
13. Sylla BS, Hung SC, Davidson DM, Hatzivassiliou E, Malinin NL, Wallach D, Gilmore TD, Kieff E, Mosialos G. 1998. Epstein-Barr virustransforming protein latent infection membrane protein 1 activates transcription factor NF-kappaB through a pathway that includes the NFkappaB-inducing kinase and the IkappaB kinases IKKalpha and IKKbeta. Proc. Natl. Acad. Sci. U. S. A. 95:10106-10111.
14. Devergne O, Cahir McFarland ED, Mosialos G, Izumi KM, Ware CF, Kieff E. 1998. Role of the TRAF binding site and NF-kappaB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J. Virol. 72:7900-7908.
15. He Z, Xin B, Yang X, Chan C, Cao L. 2000. Nuclear factor-kappaB activation is involved in LMP1-mediated transformation and tumorigenesis of rat-1 fibroblasts. Cancer Res. 60:1845-1848.
16. Mehl AM, Floettmann JE, Jones M, Brennan P, Rowe M. 2001. Characterization of intercellular adhesion molecule-1 regulation by Epstein-Barr virus-encoded latent membrane protein-1 identifies pathways that cooperate with nuclear factor kappa B to activate transcription. J. Biol. Chem. 276:984-992.
17. Pai S, O'Sullivan BJ, Cooper L, Thomas R, Khanna R. 2002. RelB nuclear translocation mediated by C-terminal activator regions of Epstein-Barr virus-encoded latent membrane protein 1 and its effect on antigen-presenting function in B cells. J. Virol. 76:1914-1921.
18. Zhang L, Wu L, Hong K, Pagano JS. 2001. Intracellular signaling molecules activated by Epstein-Barr virus for induction of interferon regulatory factor 7. J. Virol. 75:12393-12401.
19. Bassères DS, Baldwin AS. 2006. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25:6817-6830.
20. Arcipowski KM, Stunz LL, Graham JP, Kraus ZJ, Vanden Bush TJ, Bishop GA. 2011. Molecular mechanisms of TNFR-associated factor 6 (TRAF6) utilization by the oncogenic viral mimic of CD40, latent membrane protein 1 (LMP1). J. Biol. Chem. 286:9948-9955.
21. Friedman CS, O'Donnell MA, Legarda-Addison D, Ng A, Cardenas WB, Yount JS, Moran TM, Basler CF, Komuro A, Horvath CM, Xavier R, Ting AT. 2008. The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response. EMBO Rep. 9:930-936.
22. Kayagaki N, Phung Q, Chan S, Chaudhari R, Quan C, O'Rourke KM, Eby M, Pietras E, Cheng G, Bazan JF, Zhang Z, Arnott D, Dixit VM. 2007. DUBA: a deubiquitinase that regulates type I interferon production. Science 318:1628-1632.
23. Wertz IE, Dixit VM. 2010. Signaling to NF-kappaB: regulation by ubiquitination. Cold Spring Harb. Perspect. Biol. 2:a003350. doi:10.1101 /cshperspect.a003350.
24. Brown HJ, Song MJ, Deng H, Wu TT, Cheng G, Sun R. 2003. NFkappaB inhibits gammaherpesvirus lytic replication. J. Virol. 77:8532-8540.
25. Prince S, Keating S, Fielding C, Brennan P, Floettmann E, Rowe M. 2003. Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms. J. Virol. 77:5000-5007.
26. Rowe M, Lear AL, Croom-Carter D, Davies AH, Rickinson AB. 1992. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J. Virol. 66:122-131.
27. Whitehurst CB, Ning S, Bentz GL, Dufour F, Gershburg E, Shackelford J, Langelier Y, Pagano JS. 2009. The Epstein-Barr virus (EBV) deubiquitinating enzyme BPLF1 reduces EBV ribonucleotide reductase activity. J. Virol. 83:4345-4353.
28. Gastaldello S, Hildebrand S, Faridani O, Callegari S, Palmkvist M, Di Guglielmo C, Masucci MG. 2010. A deneddylase encoded by Epstein-Barr virus promotes viral DNA replication by regulating the activity of cullin-RING ligases. Nat. Cell Biol. 12:351-361.
29. Whitehurst CB, Vaziri C, Shackelford J, Pagano JS. 2012. Epstein-Barr virus BPLF1 deubiquitinates PCNA and attenuates Pol{square} recruitment to DNA damage sites. J. Virol. 86:8097-8106.
30. Maruo S, Yang L, Takada K. 2001. Roles of Epstein-Barr virus glycoproteins gp350 and gp25 in the infection of human epithelial cells. J. Gen. Virol. 82:2373-2383.
31. Noda C, Murata T, Kanda T, Yoshiyama H, Sugimoto A, Kawashima D, Saito S, Isomura H, Tsurumi T. 2011. Identification and characterization of CCAAT enhancer-binding protein (C/EBP) as a transcriptional activator for Epstein-Barr virus oncogene latent membrane protein 1. J. Biol. Chem. 286:42524-42533.
32. Murata T, Isomura H, Yamashita Y, Toyama S, Sato Y, Nakayama S, Kudoh A, Iwahori S, Kanda T, Tsurumi T. 2009. Efficient production of infectious viruses requires enzymatic activity of Epstein-Barr virus protein kinase. Virology 389:75-81.
33. Delecluse HJ, Hilsendegen T, Pich D, Zeidler R, Hammerschmidt W. 1998. Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc. Natl. Acad. Sci. U. S. A. 95:8245-8250.
34. Isomura H, Tsurumi T, Stinski MF. 2004. Role of the proximal enhancer of the major immediate-early promoter in human cytomegalovirus replication. J. Virol. 78:12788-12799.
35. Murata T, Shimotohno K. 2006. Ubiquitination and proteasomedependent degradation of human eukaryotic translation initiation factor 4E. J. Biol. Chem. 281:20788-20800.
36. Sompallae R, Gastaldello S, Hildebrand S, Zinin N, Hassink G, Lindsten K, Haas J, Persson B, Masucci MG. 2008. Epstein-Barr virus encodes three bona fide ubiquitin-specific proteases. J. Virol. 82:10477-10486.
37. Iwahori S, Murata T, Kudoh A, Sato Y, Nakayama S, Isomura H, Kanda T, Tsurumi T. 2009. Phosphorylation of p27Kip1 by Epstein-Barr virus protein kinase induces its degradation through SCFSkp2 ubiquitin ligase actions during viral lytic replication. J. Biol. Chem. 284:18923-18931.
38. Kanda T, Yajima M, Ahsan N, Tanaka M, Takada K. 2004. Production of high-titer Epstein-Barr virus recombinants derived from Akata cells by using a bacterial artificial chromosome system. J. Virol. 78:7004-7015.
39. Kudoh A, Fujita M, Kiyono T, Kuzushima K, Sugaya Y, Izuta S, Nishiyama Y, Tsurumi T. 2003. Reactivation of lytic replication from B cells latently infected with Epstein-Barr virus occurs with high S-phase cyclin-dependent kinase activity while inhibiting cellular DNA replication. J. Virol. 77:851-861.
40. Tsurumi T, Kobayashi A, Tamai K, Daikoku T, Kurachi R, Nishiyama Y. 1993. Functional expression and characterization of the Epstein-Barr virus DNA polymerase catalytic subunit. J. Virol. 67:4651-4658.
41. Tsurumi T, Kobayashi A, Tamai K, Yamada H, Daikoku T, Yamashita Y, Nishiyama Y. 1996. Epstein-Barr virus single-stranded DNA-binding protein: purification, characterization, and action on DNA synthesis by the viral DNA polymerase. Virology 222:352-364.
42. Yokoyama N, Fujii K, Hirata M, Tamai K, Kiyono T, Kuzushima K, Nishiyama Y, Fujita M, Tsurumi T. 1999. Assembly of the Epstein-Barr virus BBLF4, BSLF1 and BBLF2/3 proteins and their interactive properties. J. Gen. Virol. 80(Pt 11):2879-2887.
43. Harlow E, Lane D. 2006. Immunoprecipitation: denaturing lysis. CSH Protoc. 2006:pdb.prot4534. doi:10.1101/pdb.prot4534.
44. Nakayama S, Murata T, Yasui Y, Murayama K, Isomura H, Kanda T, Tsurumi T. 2010. Tetrameric ring formation of Epstein-Barr virus polymerase processivity factor is crucial for viral replication. J. Virol. 84: 12589-12598.
45. Murata T, Kondo Y, Sugimoto A, Kawashima D, Saito S, Isomura H, Kanda T, Tsurumi T. 2012. Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells. J. Virol. 86:4752-4761.
46. Cahir-McFarland ED, Davidson DM, Schauer SL, Duong J, Kieff E. 2000. NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc. Natl. Acad. Sci. U. S. A. 97:6055-6060.
47. Kurokawa M, Ghosh SK, Ramos JC, Mian AM, Toomey NL, Cabral L, Whitby D, Barber GN, Dittmer DP, Harrington WJ, Jr. 2005. Azidothymidine inhibits NF-kappaB and induces Epstein-Barr virus gene expression in Burkitt lymphoma. Blood 106:235-240.
48. Liu SF, Wang H, Lin XC, Xiang H, Deng XY, Li W, Tang M, Cao Y. 2008. NF-kappaB inhibitors induce lytic cytotoxicity in Epstein-Barr virus-positive nasopharyngeal carcinoma cells. Cell Biol. Int. 32:1006-1013.
49. Miyake A, Dewan MZ, Ishida T, Watanabe M, Honda M, Sata T, Yamamoto N, Umezawa K, Watanabe T, Horie R. 2008. Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NFkappaB inhibitor DHMEQ. Microbes Infect. 10:748-756.
50. Lukac DM, Garibyan L, Kirshner JR, Palmeri D, Ganem D. 2001. DNA binding by Kaposi's sarcoma-associated herpesvirus lytic switch protein is necessary for transcriptional activation of two viral delayed early promoters. J. Virol. 75:6786-6799.
51. Ledebur HC, Parks TP. 1995. Transcriptional regulation of the intercellular adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells. Essential roles of a variant NF-kappa B site and p65 homodimers. J. Biol. Chem. 270:933-943.
52. Li J, Brasier AR. 1996. Angiotensinogen gene activation by angiotensin II is mediated by the rel A (nuclear factor-kappaB p65) transcription factor: one mechanism for the renin angiotensin system positive feedback loop in hepatocytes. Mol. Endocrinol. 10:252-264.
53. Rahman A, Anwar KN, True AL, Malik AB. 1999. Thrombin-induced p65 homodimer binding to downstream NF-kappa B site of the promoter mediates endothelial ICAM-1 expression and neutrophil adhesion. J. Immunol. 162:5466-5476.
54. Stylianou E, Nie M, Ueda A, Zhao L. 1999. c-Rel and p65 trans-activate the monocyte chemoattractant protein-1 gene in interleukin-1 stimulated mesangial cells. Kidney Int. 56:873-882. 55. Hoberg JE, Yeung F, Mayo MW. 2004. SMRT derepression by the IkappaB kinase alpha: a prerequisite to NF-kappaB transcription and survival. Mol. Cell 16:245-255.
55. Hoberg JE, Yeung F, Mayo MW. 2004. SMRT derepression by the IkappaB kinase alpha: a prerequisite to NF-kappaB transcription and survival. Mol. Cell 16:245-255.
56. Hsu M, Wu SY, Chang SS, Su IJ, Tsai CH, Lai SJ, Shiau AL, Takada K, Chang Y. 2008. Epstein-Barr virus lytic transactivator Zta enhances chemotactic activity through induction of interleukin-8 in nasopharyngeal carcinoma cells. J. Virol. 82:3679-3688.
57. Miyamoto S, Maki M, Schmitt MJ, Hatanaka M, Verma IM. 1994. Tumor necrosis factor alpha-induced phosphorylation of I kappa B alpha is a signal for its degradation but not dissociation from NF-kappa B. Proc. Natl. Acad. Sci. U. S. A. 91:12740-12744.
58. Morrison TE, Kenney SC. 2004. BZLF1, an Epstein-Barr virus immediate-early protein, induces p65 nuclear translocation while inhibiting p65 transcriptional function. Virology 328:219-232.
59. Erickson KD, Berger C, Coffin WF 3rd, Schiff E, Walling DM, Martin JM. 2003. Unexpected absence of the Epstein-Barr virus (EBV) lyLMP-1 open reading frame in tumor virus isolates: lack of correlation between Met129 status and EBV strain identity. J. Virol. 77:4415-4422.
60. Pandya J, Walling DM. 2006. Oncogenic activity of Epstein-Barr virus latent membrane protein 1 (LMP-1) is down-regulated by lytic LMP-1. J. Virol. 80:8038-8046.
61. de Oliveira DE, Ballon G, Cesarman E. 2010. NF-kappaB signaling modulation by EBV and KSHV. Trends Microbiol. 18:248-257. 62. Wang G, Chen G, Zheng D, Cheng G, Tang H. 2011. PLP2 of mouse hepatitis virus A59 (MHV-A59) targets TBK1 to negatively regulate cellu-lar type I interferon signaling pathway. PLoS One 6:e17192. doi:10.1371 /journal.pone.0017192.
62. Wang G, Chen G, Zheng D, Cheng G, Tang H. 2011. PLP2 of mouse hepatitis virus A59 (MHV-A59) targets TBK1 to negatively regulate cellu-lar type I interferon signaling pathway. PLoS One 6:e17192. doi:10.1371 /journal.pone.0017192.
63. Inn KS, Lee SH, Rathbun JY, Wong LY, Toth Z, Machida K, Ou JH, Jung JU. 2011. Inhibition of RIG-I-mediated signaling by Kaposi's sarcoma-associated herpesvirus-encoded deubiquitinase ORF64. J. Virol. 85: 10899-10904.
64. Wang D, Fang L, Li P, Sun L, Fan J, Zhang Q, Luo R, Liu X, Li K, Chen H, Chen Z, Xiao S. 2011. The leader proteinase of foot-and-mouth disease virus negatively regulates the type I interferon pathway by acting as a viral deubiquitinase. J. Virol. 85:3758-3766.
65. Schoggins JW, Rice CM. 2011. Interferon-stimulated genes and their antiviral effector functions. Curr. Opin. Virol. 1:519-525. 66. Brasier AR, Li J. 1996. Mechanisms for inducible control of angiotensinogen gene transcription. Hypertension 27:465-475.
66. Brasier AR, Li J. 1996. Mechanisms for inducible control of angiotensinogen gene transcription. Hypertension 27:465-475.
67. Burns MJ, Sellati TJ, Teng EI, Furie MB. 1997. Production of interleukin-8 (IL-8) by cultured endothelial cells in response to Borrelia burgdorferi occurs independently of secreted [corrected] IL-1 and tumor necrosis factor alpha and is required for subsequent transendothelial migration of neutrophils. Infect. Immun. 65:1217-1222.
68. Tam FW, Karkar AM, Smith J, Yoshimura T, Steinkasserer A, Kurrle R, Langner K, Rees AJ. 1996. Differential expression of macrophage inflammatory protein-2 and monocyte chemoattractant protein-1 in experimental glomerulonephritis. Kidney Int. 49:715-721.
69. Wenzel U, Schneider A, Valente AJ, Abboud HE, Thaiss F, Helmchen UM, Stahl RA. 1997. Monocyte chemoattractant protein-1 mediates monocyte/macrophage influx in anti-thymocyte antibody-induced glomerulonephritis. Kidney Int. 51:770-776.
70. Boyd AW, Wawryk SO, Burns GF, Fecondo JV. 1988. Intercellular adhesion molecule 1 (ICAM-1) has a central role in cell-cell contactmediated immune mechanisms. Proc. Natl. Acad. Sci. U. S. A. 85:3095-3099.
71. Dustin ML, Springer TA. 1991. Role of lymphocyte adhesion receptors in transient interactions and cell locomotion. Annu. Rev. Immunol. 9:27-66.
72. Rothlein R, Dustin ML, Marlin SD, Springer TA. 1986. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J. Immunol. 137:1270-1274.
73. van de Stolpe A, van der Saag PT. 1996. Intercellular adhesion molecule-1. J. Mol. Med. (Berl) 74:13-33.
74. Schmaus S, Wolf H, Schwarzmann F. 2004. The reading frame BPLF1 of Epstein-Barr virus: a homologue of herpes simplex virus protein VP16. Virus Genes 29:267-277.
75. Desai PJ. 2000. A null mutation in the UL36 gene of herpes simplex virus type 1 results in accumulation of unenveloped DNA-filled capsids in the cytoplasm of infected cells. J. Virol. 74:11608-11618.
76. Roberts AP, Abaitua F, O'Hare P, McNab D, Rixon FJ, Pasdeloup D. 2009. Differing roles of inner tegument proteins pUL36 and pUL37 during entry of herpes simplex virus type 1. J. Virol. 83:105-116.
77. Böttcher S, Granzow H, Maresch C, Mohl B, Klupp BG, Mettenleiter TC. 2007. Identification of functional domains within the essential large tegument protein pUL36 of pseudorabies virus. J. Virol. 81:13403-13411.
78. Fuchs W, Klupp BG, Granzow H, Mettenleiter TC. 2004. Essential function of the pseudorabies virus UL36 gene product is independent of its interaction with the UL37 protein. J. Virol. 78:11879-11889.
79. Kim ET, Oh SE, Lee YO, Gibson W, Ahn JH. 2009. Cleavage specificity of the UL48 deubiquitinating protease activity of human cytomegalovirus and the growth of an active-site mutant virus in cultured cells. J. Virol. 83:12046-12056.
80. Ariza ME, Glaser R, Kaumaya PT, Jones C, Williams MV. 2009. The EBV-encoded dUTPase activates NF-kappa B through the TLR2 and MyD88-dependent signaling pathway. J. Immunol. 182:851-859.
81. Nijmeijer S, Leurs R, Smit MJ, Vischer HF. 2010. The Epstein-Barr virus-encoded G protein-coupled receptor BILF1 hetero-oligomerizes with human CXCR4, scavenges Galphai proteins, and constitutively impairs CXCR4 functioning. J. Biol. Chem. 285:29632-29641.
82. Beisser PS, Verzijl D, Gruijthuijsen YK, Beuken E, Smit MJ, Leurs R, Bruggeman CA, Vink C. 2005. The Epstein-Barr virus BILF1 gene encodes a G protein-coupled receptor that inhibits phosphorylation of RNA-dependent protein kinase. J. Virol. 79:441-449.
83. Soni V, Cahir-McFarland E, Kieff E. 2007. LMP1 TRAFficking activates growth and survival pathways. Adv. Exp. Med. Biol. 597:173-187.